Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irosustat in ER+ Endometrial Cancer
NCT01251354Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Nov 2010
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of irosustat in endometrial cancer (EC), sponsored by Ipsen. Primary endpoint: Clinical Benefit (CB) at 12 weeks. Started Nov 2010; status: terminated.
02
Drugs
irosustat
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT01251354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01251354.